Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

The phase 3 ICONIC-TOTAL trial has been evaluating the drug in adults and adolescents aged 12 years and older with at least moderate plaque psoriasis affecting high-impact skin sites. It is estimated ...

Icotrokinra is the first investigational, oral peptide designed to selectively block interleukin-23 receptors in people with moderate to severe plaque psoriasis, ulcerative colitis and other ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

The pop star's toenail issue ended up impacting her 2023 Met Gala outfit Lizzo on Ziwe Lizzo revealed that she had to wear closed-toed shoes for a year after losing her toenail The pop star ...

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...